Pancreatic Cancer Research

ResearcherLyon 1 UniversitéActive in the last 2 years

Philippe Alexandre Cassier

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3857-1688; OpenAlex author ID A5027371764. Sources: ClinicalTrials.gov.

Their work

Papers
7 (first author 0, last author 2)
Trials
4 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2016: 1 trial · 2017: none · 2018: none · 2019: 1 paper, 1 trial · 2020: 1 paper, 1 trial · 2021: 1 paper · 2022: 1 trial · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 7

  1. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2600752↗
  2. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  3. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗
  4. Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial. Last author DOI 10.1158/1078-0432.ccr-23-2893↗
  5. Autophagy as a therapeutic target in pancreatic cancer. Last author DOI 10.1038/s41416-020-01039-5↗
  6. Correction: Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Co-author DOI 10.1038/s41419-020-2262-1↗
  7. Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Co-author DOI 10.1038/s41419-019-2116-x↗

Trials 4

  1. Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients Principal investigator NCT05380414↗
  2. PATAKESS Protocol : Clinical and Biological Analysis of Exocrine Pancreatic Tumors Principal investigator NCT04011982↗
  3. Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma Principal investigator NCT03871959↗
  4. Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic… Principal investigator NCT02777710↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 3 shared papers, 2024–2026 · strength 0.55
  2. Emmanuel Mitry · 2 shared papers, 2024–2025 · strength 0.36
  3. Jean‐Frédéric Blanc · 2 shared papers, 2024–2025 · strength 0.36
  4. Hans Prenen · 2 shared papers, 2024–2025 · strength 0.36
  5. Jean‐Luc Van Laethem · 2 shared papers, 2024–2025 · strength 0.36
  6. Karen Paula Geboes · 2 shared papers, 2024–2025 · strength 0.36
  7. Lorenzo Pilla · 2 shared papers, 2024–2025 · strength 0.36
  8. Roberto Pazo-Cid · 2 shared papers, 2024–2025 · strength 0.36
  9. Aurélien Lambert · 2 shared papers, 2024–2025 · strength 0.36
  10. Jaime Feliú · 2 shared papers, 2024–2025 · strength 0.36
  11. Max Piffoux · 1 shared paper, 2021 · strength 0.22
  12. Wungki Park · 1 shared paper, 2026 · strength 0.19
  13. Antoîne Italiano · 1 shared paper, 2026 · strength 0.19
  14. Hirokazu Shoji · 1 shared paper, 2026 · strength 0.19
  15. Antoine Hollebecque · 1 shared paper, 2026 · strength 0.19
  16. Makoto Ueno · 1 shared paper, 2026 · strength 0.19
  17. Anup Kasi · 1 shared paper, 2026 · strength 0.19
  18. Patricia Mucci LoRusso · 1 shared paper, 2026 · strength 0.19
  19. Jordan D. Berlin · 1 shared paper, 2026 · strength 0.19
  20. Pasi Antero Janne · 1 shared paper, 2026 · strength 0.19
  21. Christos K Fountzilas · 1 shared paper, 2026 · strength 0.19
  22. Jonathan Wade Goldman · 1 shared paper, 2026 · strength 0.19
  23. Benoît You · 1 shared paper, 2026 · strength 0.19
  24. Alexander I. Spira · 1 shared paper, 2026 · strength 0.19
  25. Eileen Mary O'Reilly · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.